Biopharmaceutical companies have traditionally considered outsourcing as a way to control costs and manage their internal resources to make the core activities left in-house more efficient.
Biopharmaceutical companies have traditionally considered outsourcing as a way to control costs and manage their internal resources to make the core activities left in-house more efficient. But in recent years, surveys of biopharmaceutical manufacturers by BioPlan Associates have shown that cost cutting is, by far, not the primary reason companies outsource anymore.
Advertisement
In fact, this factor ranks far below other measures. New data from the 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production indicate that cost control is becoming less of a driver of outsourcing activity.
For Eric Langer’s Pharmaceutical Technology article on these results, click here.
